Academic Journal
Q1Annals of Oncology
About Annals of Oncology
Annals of Oncology is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 21.715 and an H-index of 331.
Its listed coverage is 1990-2026 and its research categories include Hematology (Q1); Medicine (miscellaneous) (Q1); Oncology (Q1). The 2025 dataset reports 244 documents and 12368 citations across the latest three-year reporting window.
The Annals of Oncology is a prestigious, peer-reviewed scientific journal that has established itself as a key resource for oncologists, researchers, and healthcare professionals involved in cancer care. Published monthly, the journal focuses on providing in-depth insights into the latest developments in cancer research, clinical oncology, and the advancements in cancer treatment. It plays a vital role in the global oncology community by disseminating high-quality research and offering evidence-based practices for clinicians and researchers alike.
Key Areas of Focus in Annals of Oncology
The journal covers a wide range of topics related to cancer, including but not limited to:
-
Cancer Treatment Advances: With a strong emphasis on cutting-edge therapies, Annals of Oncology publishes articles on the latest breakthroughs in cancer treatments. This includes immunotherapy, targeted therapies, chemotherapy, and radiation therapy. It also explores new methods for improving treatment outcomes and minimizing side effects.
-
Clinical Trials and Research: Clinical trials are an essential part of advancing cancer treatment, and Annals of Oncology provides comprehensive coverage of ongoing and completed trials. The journal often includes phase I-III trial results, offering valuable data that can shape treatment protocols and influence the clinical management of cancer.
-
Oncology Diagnostics: The journal highlights advancements in diagnostic tools, such as molecular profiling, imaging techniques, and biomarker discovery, which are critical for early cancer detection and personalized treatment planning.
-
Cancer Epidemiology and Prevention: Understanding the epidemiological trends of cancer and implementing effective prevention strategies are crucial to reducing cancer incidence worldwide. Annals of Oncology regularly publishes studies on cancer risk factors, screening methods, and public health initiatives aimed at preventing cancer.
-
Personalized Medicine in Oncology: One of the journal’s key areas of interest is personalized medicine, focusing on how genetic, molecular, and environmental factors influence cancer treatment decisions. Articles often explore the growing importance of precision oncology and how genomic data can guide targeted therapies tailored to individual patients.
Why Annals of Oncology is a Critical Resource for Oncologists
The Annals of Oncology is a trusted publication for oncologists worldwide due to its rigorous peer-review process and its commitment to publishing high-quality, impactful research. For healthcare providers and researchers, staying updated with the latest findings in cancer care is essential for improving patient outcomes. The journal provides a platform for the dissemination of groundbreaking research that influences clinical practices, shaping the future of cancer treatment.
Global Impact and Accessibility
As one of the most highly cited oncology journals globally, Annals of Oncology reaches a vast audience. Its content is accessible to clinicians, researchers, and students, helping to bridge the gap between laboratory discoveries and clinical applications. The journal’s impact factor and high citation rates reflect its importance and contribution to advancing cancer care and research.
Moreover, Annals of Oncology is available online, ensuring easy access to research findings, reviews, and special articles. The journal’s website also offers features such as early online publication of high-impact articles, making it an up-to-date and reliable source of information.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The Annals of Oncology is one of the most renowned and influential journals in the field of oncology. It serves as a critical platform for publishing high-quality research and advancements in cancer treatment, prevention, and management. The journal offers valuable insights for clinicians, researchers, and healthcare professionals working in the field of oncology. As a leading publication in the field, Annals of Oncology plays a pivotal role in advancing our understanding of cancer biology, providing evidence-based approaches, and improving patient outcomes.
Focus Areas and Key Topics
The scope of the Annals of Oncology covers a wide array of cancer-related disciplines, making it an essential resource for oncologists and medical researchers worldwide. Its primary focus is to publish groundbreaking research in various areas of oncology, including but not limited to:
-
Cancer Biology and Molecular Pathways: The journal features studies on the molecular mechanisms underlying cancer, exploring the genetic mutations, signaling pathways, and cellular processes that drive tumorigenesis. Research in this area provides insights into potential biomarkers for early detection and targets for innovative therapies.
-
Clinical Oncology: Clinical oncology is a significant area of interest for the Annals of Oncology. The journal publishes research on the diagnosis, treatment, and management of cancers across a wide range of organs and tissues. Topics such as personalized medicine, immunotherapy, chemotherapy, radiotherapy, and surgical interventions are frequently covered. The journal emphasizes evidence-based approaches that improve patient care and treatment outcomes.
-
Cancer Prevention and Epidemiology: Cancer prevention is an increasingly important topic in the fight against cancer. Annals of Oncology publishes studies focused on the prevention of cancer through lifestyle changes, vaccination, early screening, and other preventive measures. Additionally, epidemiological studies on the global burden of cancer and its impact on different populations are key components of the journal’s scope.
-
Immuno-Oncology: Immunotherapy has become one of the most promising areas of cancer treatment in recent years. The Annals of Oncology features research on novel immuno-oncology strategies, including checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. These studies aim to explore how the immune system can be harnessed to target and eliminate cancer cells effectively.
-
Palliative Care and Survivorship: Palliative care is essential for improving the quality of life for patients with advanced cancer. The Annals of Oncology also publishes research on palliative care strategies, symptom management, and psychosocial support for cancer patients. Additionally, survivorship care, including the long-term effects of cancer treatment and strategies for monitoring and supporting survivors, is a critical area of focus.
-
Oncology Nursing and Multidisciplinary Care: The journal recognizes the importance of a multidisciplinary approach to cancer care. Research related to oncology nursing, the role of allied health professionals, and the integration of different specialties in cancer treatment is a key part of the journal’s scope.
Peer-Reviewed Research and Global Collaboration
As a peer-reviewed journal, Annals of Oncology ensures that all submitted manuscripts undergo a rigorous review process by experts in the field. This process guarantees the quality and credibility of the published research. The journal encourages international collaboration, providing a platform for researchers from diverse geographical regions to share their findings and contribute to the global fight against cancer.
Recent Research Articles
Latest publications matched automatically by ISSN.
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
E. de Azambuja, C.H. Barrios, R. Bartsch, G. Curigliano et al.
2026-09 · DOI: 10.1016/j.annonc.2026.05.707Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial
M. Dugo, C.-S. Huang, D. Egle, B. Bermejo et al.
2026-09 · DOI: 10.1016/j.annonc.2026.05.694Corrigendum to ‘Subcutaneous versus intravenous nivolumab for renal cell carcinoma’
L. Albiges, M.T. Bourlon, M. Chacón, H.J. Cutuli et al.
2026-09 · DOI: 10.1016/j.annonc.2026.03.007Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial
O. Pagani, S.M. Niman, M. Ruggeri, F.A. Peccatori et al.
2026-09 · DOI: 10.1016/j.annonc.2026.05.699Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology
T. Cantore, D.-T. Hoang, L.R. Pal, A. Stemmer et al.
2026-09 · DOI: 10.1016/j.annonc.2026.05.700“Overall survival with abemaciclib in early breast cancer”
Francesca Poggio, Daniele Generali
2026-09 · DOI: 10.1016/j.annonc.2026.08.008Erratum to ‘Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis’
H.S. Rugo, E. Tokunaga, H. Iwata, V. Petry et al.
2026-09 · DOI: 10.1016/j.annonc.2025.12.001Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study
A.T. Shaw, B.J. Solomon, E. Felip, T.M. Bauer et al.
2026-09 · DOI: 10.1016/j.annonc.2026.05.692Overall survival according to COVID-19 mRNA vaccination co-exposure in patients treated with PD-(L)1 inhibitors: a French real-world cohort study
H. Jourdain, N. Haddy, A. Singier, T. Duchemin et al.
2026-08 · DOI: 10.1016/j.annonc.2026.05.002Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
R. Dent, Z. Shao, P. Schmid, J. Cortes et al.
2026-08 · DOI: 10.1016/j.annonc.2026.03.008Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial
D. Juric, H.S. Rugo, A. Reising, K. Vervier et al.
2026-08 · DOI: 10.1016/j.annonc.2026.04.003Towards the practical use of AI: a tool for scalable colorectal cancer screening
E.Y.T. Wong, A. Plumb, K.K. Shiu
2026-08 · DOI: 10.1016/j.annonc.2026.06.017Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
A. Mavrikios, M. Bortolot, C. Le Péchoux, J. Remon et al.
2026-08 · DOI: 10.1016/j.annonc.2026.04.014Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
Y. Wang, D. Drubay, S.F. Jonas, J. Dixon-Douglas et al.
2026-08 · DOI: 10.1016/j.annonc.2026.04.011Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
H. Wakelee, J.D. Spicer, S. Gao, M. Liberman et al.
2026-08 · DOI: 10.1016/j.annonc.2026.08.005Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
J.E. Garber, D. Cameron, C. Campbell, G. Yothers et al.
2026-08 · DOI: 10.1016/j.annonc.2026.08.002Editorial Board
2026-08 · DOI: 10.1016/s0923-7534(26)00974-9The return of the adult thymus in radiation oncology?
A. Levy, D. Morel, L. Meziani, M. Mondini et al.
2026-08 · DOI: 10.1016/j.annonc.2026.07.410Colorectal cancer detection using noncontrast CT and deep learning: a multicenter and international cohort study
X. Chen, M.Y. Qiu, J.P. Zhang, Y.D. Xia et al.
2026-08 · DOI: 10.1016/j.annonc.2026.04.009ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word
N. Tarazona, A. Parikh
2026-08 · DOI: 10.1016/j.annonc.2026.06.002Reviews
Community Reviews
Version History
April 14, 2025 at 11:05 am
March 20, 2025